Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection.
On Tuesday, Clearmind Medicine Inc (NASDAQ:CMND) submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd (NASDAQ:SPRC). The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide. These were previously filed as provisional pate
For the first time, patients with alcohol use disorder will receive the company s unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23,.
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Clearmind Medicine (CMND) Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.